84 results
Page 2 of 5
8-K
EX-10.1
w8a55i
16 Mar 22
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At the Market
8:30am
424B5
1mw9axy6
16 Mar 22
Prospectus supplement for primary offering
8:00am
8-K
EX-10.1
bwjiechqcdqe 2063
7 Feb 22
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
4:00pm
8-K
EX-99.1
r35etrnka
10 Jan 22
Other Events
8:00am
8-K
EX-10.1
loslk 1u8
7 Dec 21
Departure of Directors or Certain Officers
6:15am
8-K
EX-10.1
rrhqvbg8dg taovo
7 Sep 21
Entry into a Material Definitive Agreement
4:16pm
8-K
EX-99.2
crfwztxy7xz iqp
6 May 21
Axcella Reports First Quarter Financial Results and Provides Business Update
7:51am
8-K
EX-10.1
kvjcr yjo6oh35p2yi
3 Mar 21
Axcella Announces Alison D. Schecter, M.D., as President of R&D
5:26pm
S-3
10mkft3
5 Jun 20
Shelf registration
5:02pm
S-3
EX-4.3
74seh s3ntlldolg
5 Jun 20
Shelf registration
5:02pm